Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-24 @ 11:44 PM
NCT ID:
NCT00039351
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma (NHL)
* No Burkitt's-like lymphoma
* Small cells in bone marrow allowed
* Previously untreated NHL
* At least 1 measurable lesion
* At least 1.1 cm
* Poor physiological status with at least 1 of the following:
* WHO performance status of 3-4
* LVEF less than 50%
* Creatinine clearance less than 50 mL/min
* Neutrophil count no greater than 1,500/mm\^3
* Platelet count no greater than 100,000/mm\^3
* Concurrent severe disease that would preclude cyclophosphamide, vincristine, prednisolone, and doxorubicin
* No cerebral or meningeal involvement
PATIENT CHARACTERISTICS:
Age:
* 70 and over
Performance status:
* See Disease Characteristics
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Not specified
Renal:
* See Disease Characteristics
Other:
* HIV negative
* No other malignancy within the past 5 years except adequately treated basal cell skin cancer, curatively treated carcinoma in situ of the cervix, or curatively treated solid tumor
* No active infection
* No psychological, familial, sociological, or geographical condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No other concurrent investigational drugs
* No other concurrent antineoplastic agents
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
70 Years
Study:
NCT00039351
Study Brief:
Protocol Section:
NCT00039351